Commentary/Editorials

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
Fei Zhou, Wencheng Zhao, Xiaomei Gong, Shengxiang Ren, Chunxia Su, Tao Jiang, Caicun Zhou

Journal for ImmunoTherapy of Cancer Sep 2020, 8 (2) e001300; DOI: 10.1136/jitc-2020-001300
Tracking the tail
Alex Friedlaender, Stephen V Liu, Alfredo Addeo

Journal for ImmunoTherapy of Cancer Sep 2020, 8 (2) e000971; DOI: 10.1136/jitc-2020-000971
Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e000952; DOI: 10.1136/jitc-2020-000952
BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy
Madhuri Koti, Alvaro Morales, Charles H Graham, David Robert Siemens

Journal for ImmunoTherapy of Cancer Jul 2020, 8 (2) e001119; DOI: 10.1136/jitc-2020-001119
Influence of gut microbiome on multiple myeloma: friend or foe?
Nausheen Ahmed, Mahmoud Ghannoum, Molly Gallogly, Marcos de Lima, Ehsan Malek

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000576; DOI: 10.1136/jitc-2020-000576
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy
John Haanen, Marc Ernstoff, Yinghong Wang, Alexander Menzies, Igor Puzanov, Petros Grivas, James Larkin, Solange Peters, John Thompson, Michel Obeid

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000604; DOI: 10.1136/jitc-2020-000604
Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?
Catalin Constantinescu, Sergiu Pasca, Tiberiu Tat, Patric Teodorescu, Catalin Vlad, Sabina Iluta, Delia Dima, Dana Tomescu, Ecaterina Scarlatescu, Alina Tanase, Olafur Eysteinn Sigurjonsson, Anca Colita, Hermann Einsele, Ciprian Tomuleasa

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000742; DOI: 10.1136/jitc-2020-000742
COVID-19 and immune checkpoint inhibitors: initial considerations
Ryan J Sullivan, Douglas B Johnson, Brian I Rini, Tomas G Neilan, Christine M Lovly, Javid J Moslehi, Kerry L Reynolds

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000933; DOI: 10.1136/jitc-2020-000933
COVID-19 and lung cancer: risks, mechanisms and treatment interactions
Alfredo Addeo, Michel Obeid, Alex Friedlaender

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000892; DOI: 10.1136/jitc-2020-000892
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19
Paolo Antonio Ascierto, Bernard A Fox, Walter J Urba, Ana Carrizosa Anderson, Michael B Atkins, Ernest C Borden, Julie R Brahmer, Lisa H Butterfield, Alessandra Cesano, Daniel S Chen, Tanja D de Gruijl, Robert O Dillman, Charles G Drake, Leisha A Emens, Thomas F Gajewski, James L Gulley, F Stephen Hodi Jr, Patrick Hwu, David Kaufman, Howard L Kaufman, Michael T Lotze, Douglas G McNeel, Kim A Margolin, Francesco M Marincola, Michael J Mastrangelo, Marcela V Maus, David R Parkinson, Pedro J Romero, Paul M Sondel, Stefani Spranger, Mario Sznol, George J Weiner, Jon M Wigginton, Jeffrey S Weber

Journal for ImmunoTherapy of Cancer Apr 2020, 8 (1) e000878; DOI: 10.1136/jitc-2020-000878

Main menu

Commentary/Editorials

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Commentary/Editorials

Pages